WeiCan Medical Secures Tens of Millions of Yuan in Angel Funding to Advance Innovation in Implantable Drug Delivery Devices

Recently, Weican Medical, an innovation pioneer in the field of implantable drug delivery devices in China, announced the completion of its angel round financing amounting to tens of millions of yuan.This round of financing was led byOriza HoldingsandNuoyu CapitalCo-led investment, with follow-on investment from Nanjing Jiangbei New Area Technology Investment Group Co., Ltd. The funds raised in this round will be used to accelerate the market launch of the first-generation product, speed up the R&D of next-generation products, and rapidly drive the implementation of disruptive innovative product projects.Previously, Weican Medical secured tens of millions of yuan in seed funding from Huachuang Capital.

Weican Medical, established in April 2023, specializes in the research, development, and application of new technologies for minimally invasive implantable drug delivery devices (PORTs). The company remains focused on this niche sector, striving to leverage PORTs as a platform to continuously innovate and expand into broader application scenarios. It is also accelerating the development of foundational digital and informational products to achieve revolutionary innovation in its new product offerings.

Within less than two years of its establishment, the company rapidly completed two rounds of financing, underscoring the capital market’s confidence in the market prospects of minimally invasive implantable drug delivery devices and in the founding team. Mr. Li Qiang, the founder, has cultivated deep expertise in the field of implantable drug delivery devices over many years. Through this venture, he aims to deliver greater clinical value by developing innovative implantable drug delivery systems. In 2024, Mr. Li was consecutively recognized as a High-Level Innovation and Entrepreneurship Talent under the Nanjing Zijin Mountain Talent Program and as a Science and Technology Leading Talent in Suzhou Industrial Park, while also leading the company to earn the designation of National Technology-Based Small and Medium-sized Enterprise.

Weican Medical will focus closely on the PORT niche, accumulating R&D experience, refining its products, and mastering process technologies to continuously strengthen its innovation and execution capabilities. The company has established and put into operation a Suzhou R&D center and a Nanjing production base that meet first-class standards, equipped with internationally advanced manufacturing equipment and testing instruments. Weican Medical continues to increase its R&D investment and has established collaborations with multiple universities and research institutions to drive technological innovation and product upgrades. Confident in its product advantages and technical strength, Weican Medical believes it will continue to launch innovative products that meet clinical needs and is poised to secure a significant position in the PORT market.

Peng Liwen, Investment Director of Oriza Holdings Guangzhou FundIt stated: "Clinical practice presents diverse demands for vascular access drug infusion, with infusion methods and technologies undergoing continuous iteration and upgrades. After meeting basic requirements such as safety, cost-effectiveness, and ease of use, new clinical priorities in recent years have included long-term continuous administration, localized precise delivery, aesthetics, digitalization, and intelligence. The implantable port (PORT) has emerged as a key developmental direction following mature products such as peripheral intravenous catheters, central venous catheters (CVC), and peripherally inserted central catheters (PICC). Currently, implantable drug delivery devices represent one of the fastest-growing segments within the medical device industry. The Weican team’s breakthroughs in material modification and minimally invasive surgical techniques have addressed critical shortcomings of existing products. We are optimistic that it will become an innovation benchmark in the field of vascular access."

Xu Linzhen, Investment Director of Nuoyu Capital"As a capital investor deeply committed to technological innovation, we firmly believe that true value stems from profound insights into and precise responses to human health needs. In an era marked by the accelerating trend of treating tumors as chronic conditions and a surge in demand for home-based healthcare, Weican Medical is leveraging minimally invasive implantable drug delivery devices as a fulcrum to drive innovation in the trillion-yuan chronic disease management market. Furthermore, Weican Medical perfectly aligns with the 'golden triangle' model of medtech investment, combining technical barriers (full-process independent intellectual property rights), market explosiveness (a blue-ocean market valued at RMB 5 billion), and social value (reducing healthcare costs). We are optimistic about its potential to become a benchmark enterprise for high-end domestically produced medical devices."

Weican Medical will leverage this round of financing to accelerate the advancement of its mission to “make precision medicine accessible,” reshaping the market landscape for implantable drug delivery devices through technological innovation and industrial synergy. We sincerely invite medical institutions, industry chain partners, and all sectors of society to follow our company’s development and jointly witness the rise of China’s medical technology!